Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

NCT02446444 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

802

Enrollment

OTHER

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: Enzalutamide
DRUG: Conventional NSAA
DRUG: LHRHA
RADIATION: External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)

Sponsor

University of Sydney

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]